Drug Profile
Paclitaxel - Teva Pharmaceutical Industries
Alternative Names: Paxoral; XoraneLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator IVAX Corporation
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Gastric cancer; Non-small cell lung cancer
Most Recent Events
- 16 Jan 2007 Discontinued - Phase-II for Breast cancer in USA (PO)
- 16 Jan 2007 Discontinued - Phase-II for Gastric cancer in USA (PO)
- 16 Jan 2007 Discontinued - Phase-II for Non-small cell lung cancer in USA (PO)